Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial-Reference-Cited by-同舟云学术

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Published:2015-08 Issue:9992 Volume:386 Page:444-451
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Long Georgina V,Stroyakovskiy Daniil,Gogas Helen,Levchenko Evgeny,de Braud Filippo,Larkin James,Garbe Claus,Jouary Thomas,Hauschild Axel,Grob Jean-Jacques,Chiarion-Sileni Vanna,Lebbe Celeste,Mandalà Mario,Millward Michael,Arance Ana,Bondarenko Igor,Haanen John B A G,Hansson Johan,Utikal Jochen,Ferraresi Virginia,Kovalenko Nadezhda,Mohr Peter,Probachai Volodymr,Schadendorf Dirk,Nathan Paul,Robert Caroline,Ribas Antoni,DeMarini Douglas J,Irani Jhangir G,Swann Suzanne,Legos Jeffrey J,Jin Fan,Mookerjee Bijoyesh,Flaherty Keith

Publisher

Elsevier BV

Subject

General Medicine

Reference15 articles.

1. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations;Flaherty;N Engl J Med,2012

2. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma;Long;N Engl J Med,2014

3. Improved overall survival in melanoma with combined dabrafenib and trametinib;Robert;N Engl J Med,2015

4. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009

5. Discrete sequential boundaries for clinical trials;Lan;Biometrika,1983

Cited by 1182 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant therapy for melanoma: past, present, and future;Surgical Oncology;2024-10

2. Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma;Cancer Treatment Reviews;2024-09

3. Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting;Melanoma Research;2024-08-30

4. Evidence for Radiation Therapy in Stage III Locoregionally Advanced Cutaneous Melanoma in the Post-Immunotherapy Era: A Literature Review;Cancers;2024-08-30

5. Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the “MOZART” prospective observational study;The Oncologist;2024-08-23